Panel: Resurgence of Neuroscience Drugs Development

Session details:

Neuroscience drug development is undergoing a renaissance. Advances in disease modeling, imaging, fluid biomarkers, and translational science are unlocking new possibilities in CNS disorders long considered intractable. These scientific gains—combined with a maturing clinical pipeline and growing patient demand—are sparking a new wave of investment, partnerships, and high-profile acquisitions. This panel brings together scientific and business leaders to explore how the convergence of innovation and strategic interest is reshaping the future of neuroscience therapeutics.

• From Bench to Brain: Advances in target discovery, neuroinflammation, and synaptic biology fueling early-stage innovation
• Biomarkers & Precision Neuroscience: Leveraging imaging, genetics, and fluid markers for patient stratification and trial design
• Clinical Re-Risking: What’s changed in trial methodology, endpoints, and regulatory openness for CNS programs
• M&A and Partnering Trends: How pharma is repositioning neuroscience as a core growth area—and what they’re looking for in biotech deals.